Angelo Di Leo discussed it in regard to genomic tests for prognostic purpose, but this problem is broader and the general issue is, ‘access to innovation for patients with breast cancer: how to speed it up?’ The same limitations are related to clinical practice in the case of expensive drugs to be integrated in patient management (dual targeting in HER2-positive breast cancer). The gene discussed is ERBB2; the disease is breast cancer.